

November 29, 2018

---

# Nemus Bioscience to Present at Investment and Scientific Conferences in December

Long Beach, CA, Nov. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that CEO and Chief Medical Officer Dr. Brian Murphy will present a corporate overview at the 11<sup>th</sup> Annual LD Micro Main Event. In addition, Dr. Murphy will be featured as a guest speaker at the upcoming National Center for Complementary and Integrative Health (NCCIH) Meeting and the International Cannabinoid Derived Pharmaceuticals Summit.

## 11<sup>th</sup> Annual LD Micro Main Event

Dr. Murphy will present a corporate overview at the 11th Annual LD Micro Main Event to be held on December 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Bel-Air, CA with follow-up investor meetings held throughout the conference. Details of the presentation are as follows:

- **Date and Time:** Tuesday, December 4, 2018 at 12:30 PM PST
- **Location:** Luxe Sunset Boulevard Hotel, Bel-Air, CA; Track 2

To view the live webcast, please access the following link at the time of the presentation: <http://wsb.com/webcast/ldmicro15/nmus/>. An archived version of the webcast will be available for 90 days in the investor section of the Nemus Bioscience website.

The LD Micro Invitational Conference is one of the nation's largest independent conferences for small/micro-cap companies, with more than 230 companies presenting to over 1000 attendees. The conference will also feature a variety of speakers and panelists discussing topics of interest to investors. For more information about this conference, please visit: <https://www.ldmicro.com/events>.

## National Center for Complementary and Integrative Health (NCCIH): Evaluating the Therapeutic Potential of Cannabinoids

Dr. Murphy will participate in a panel discussion at the NCCIH: Evaluating the Therapeutic Potential of Cannabinoids meeting to be held on December 8, 2018 during the annual meeting of the American College of Neuropsychopharmacology in Hollywood, Florida.. Of the companies invited to speak on this topic, Nemus Bioscience is one of only two companies who use cannabinoid-based therapies to treat unmet medical needs. Details of the presentation are as follows:

- **Session:** "Working Within the System: Advances in Cannabis-Related Production and Distribution"
- **Date and Time:** Saturday, December 8, 2018 at 1:50 PM EST
- **Location:** National Institutes of Health; via webcast

This workshop will bring together researchers, government officials, and industry representatives to discuss the processes and issues related to conducting cannabinoid research. The meeting will be held from 8:00 AM to 5:30 PM EST and will be livestreamed online. The link to view the livestream/videocast will be posted on the NCCIH website when available. For more information about this conference, please visit: <https://nccih.nih.gov>.

### **International Cannabinoid-Derived Pharmaceuticals Summit: Uniting Industry and Academia to Pioneer the Therapeutic Use of Cannabinoid APIs**

Dr. Murphy will provide a presentation at the International Cannabinoid-Derived Pharmaceuticals Summit to be held on December 11-12, 2018 at The Revere Hotel in Boston, MA. Details of the presentation are as follows:

- **Session:** “The Challenges Surrounding Funding of Cannabinoid Research and Innovating Your Business in this Growing Field”
- **Presentation Title:** “Cannabinoid Therapeutics: A Hypercompetitive Space Made for Disruption”
- **Date and Time:** Wednesday, December 12, 2018 at 4:00 PM EST
- **Location:** The Revere Hotel, Boston, MA

The summit will discuss key issues ranging from the benchside to commercialization for cannabinoid drug developers. Speakers will discuss complex cannabinoid pharmacology, formulations, clinical trials, patient education and commercial challenges. The summit will also include roundtable sessions, panel discussions, and workshops to take a deep dive into formulation and commercial strategy challenges. For more information about this conference, please visit: [www.international-cdp.com](http://www.international-cdp.com).

### **About Nemus Bioscience, Inc.**

The Company is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary biosynthetic compounds, alone or in combination with corporate partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and a significant background in early-stage drug development.

For more information, visit [www.nemusbioscience.com](http://www.nemusbioscience.com).

### **CONTACT**

Nemus Investor Relations  
PCG Advisory Group  
Adam Holdsworth  
Email: [adamh@pcgadvisory.com](mailto:adamh@pcgadvisory.com)  
Phone: 646-862-4607

Doug Cesario  
Chief Financial Officer  
Email: [doug@nemusbio.com](mailto:doug@nemusbio.com)

Phone: 949-336-3437

## **FORWARD LOOKING STATEMENTS**

This press release contains forward-looking statements, including statements regarding our product development and business strategy. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "contemplates," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Nemus may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Nemus' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Nemus disclaims any intent or obligation to update these forward-looking statements.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any securities that may be offered in the United States will be offered only to accredited investors pursuant to Regulation D of the Securities Act.



Source: Nemus Bioscience, Inc.